Altace Will Provide "Stable" Growth Platform For Three Years, King Says

King plans to tap the ACE inhibitor's market potential through expanded indications and inclusion of ramipril on hospital discharge protocols, Corporate Head of Commercial Operations Andrzejewski says. The company is targeting the second half of 2005 for NDA filings in pediatric hypertension and chronic kidney disease.